ArticleAsian Pacific journal of cancer prevention : APJCP2025
Is Cyclooxygenase 2 Effective in Breast Cancer Diagnosis?
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is considered the leading cause of death in women worldwide. When cancer is detected early, the survival rate increases significantly. Molecular identification of genes alterations and expression of specific proteins has become a key indicator of breast cancer diagnosis and treatment. COX2 is considered as one of biomarkers for different types of cancer.
objectiveThis study aimed to validate the correlation between COX2 mutation and breast cancer.
methodsUsing conventional PCR, COX2 was isolated from 57 patients after lumpectomy and from blood samples. The samples were collected from patients admitted to Al-Basrah Teaching Hospital. Forty-two samples were malignant and fifteen were benign which were used as controls for mutation and for expression. In addition, tissue from inside of tumors and far from tumor were tested to compare COX2 expression by performing of RT-PCR.
resultsThe results showed that 5 out of 12 (30.3%) samples sent to DNA sequence were mutated, three of them had deletions, while the others had substitution. All mutations were in exon2 and no mutation in exon1. Expression of COX2 in malignant was detected by RT-PCR and showed very significant difference between malignant and benign in all areas of samples, inside tumor, far from tumor tissue and blood. Significant differences in expression of COX2 in malignant lesions and blood samples of malignant, and benign tissue can be considered as a good biomarker for detection of breast cancer in suspected patients. Relatively high expression level of COX2 were recorded in patient with aged 57-66 with 39% inside malignant tumor and 13.53% far from tumor and 23.1% in blood compared with only 7.25%, 8.4% and 5.3% in benign samples in the same age group, respectively.
conclusionThese results provide insight into the ability to use COX2 as a biomarker for suspected breast cancer patients in Iraq.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.